A Prospective, Multi-centre Post Marketing Surveillance (PMS) Cohort Study to Monitor the Safety of GlaxoSmithKline (GSK) Biologicals' Human Papillomavirus (HPV)-16/18 L1 VLP AS04 Vaccine in Female Chinese Subjects Aged Between 9 and 45 Years, When Administered According to the Prescribing Information (PI) as Per Routine Practice
Latest Information Update: 13 Sep 2021
Price :
$35 *
At a glance
- Drugs Human papillomavirus vaccine recombinant bivalent Japan Vaccine/MedImmune (Primary)
- Indications Cervical cancer; Cervical intraepithelial neoplasia; Human papillomavirus infections
- Focus Adverse reactions
- Sponsors GlaxoSmithKline
- 15 Jan 2021 Status changed from active, no longer recruiting to completed.
- 15 Jun 2020 Planned End Date changed from 4 Dec 2020 to 3 Dec 2020.
- 15 Jun 2020 Planned primary completion date changed from 4 Dec 2020 to 3 Dec 2020.